Foghorn TherapeuticsFHTX
About: Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
Employees: 116
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
318% more call options, than puts
Call options by funds: $92K | Put options by funds: $22K
100% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 7
64% more capital invested
Capital invested by funds: $227M [Q2] → $372M (+$145M) [Q3]
35% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 20
10% more funds holding
Funds holding: 72 [Q2] → 79 (+7) [Q3]
0.88% more ownership
Funds ownership: 71.41% [Q2] → 72.29% (+0.88%) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Morgan Stanley Vikram Purohit 40% 1-year accuracy 2 / 5 met price target | 37%upside $9 | Equal-Weight Maintained | 24 Sept 2024 |
Financial journalist opinion
Based on 3 articles about FHTX published over the past 30 days